ISSN: 2332-0877

感染症と治療ジャーナル

オープンアクセス

当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

Epigenome Editing for Treatment of Genetic and Infectious Diseases

Jun Ueda, Hiroshi Funakoshi

Epigenome editing is fast becoming a promising technology for use in not only basic research but also various medical fields. Its applications are being studied for treatment of various diseases, including cancer, genetic diseases, and infectious diseases. Viral infections are known to cause epigenetic modifications in the host. Therefore, epigenome editing is a promising therapeutic approach which also has the capability to downregulate receptors for pathogen to enter the host. However, addressing the challenges of drug delivery systems is an essential and critical component for the success of these approaches. In this review, we briefly introduce the distinctive differences between genome editing and epigenome editing, highlight the challenges in application of the epigenome-editing approach to infectious diseases, and briefly outline the recent advances and challenges in drug delivery systems that are essential for therapeutic applications of epigenome editing. While further advances in delivery systems are needed, epigenome editing could be a potentially new generation of treatments and open new avenues for treating infectious diseases, in addition to genetic and other diseases.

免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません。